International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)

Ayalew Tefferi, Giovanni Barosi, Ruben A. Mesa, Francisco Cervantes, H. Joachim Deeg, John T. Reilly, Srdan Verstovsek, Brigitte Dupriez, Richard T. Silver, Olatoyosi Odenike, Jorge Cortes, Martha Wadleigh, Lawrence A. Solberg, John K. Camoriano, Heinz Gisslinger, Pierre Noel, Juergen Thiele, James W. Vardiman, Ronald Hoffman, Nicholas C.P. CrossD. Gary Gilliland, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis. Patients with MMM have shortened survival and their quality of life is compromised by progressive anemia, marked hepatosplenomegaly, and severe constitutional symptoms including cachexia. After decades of frustration with ineffective therapy, patients are now being served by promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and immunomodulatory drugs. Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2V617F), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response. Such progress calls for standardization of response criteria to accurately assess the value of new treatment modalities, to allow accurate comparison between studies, and to ensure that the definition of response reflects meaningful health outcome. Accordingly, an international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI). Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly.

Original languageEnglish (US)
Pages (from-to)1497-1503
Number of pages7
JournalBlood
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Stem cells
Consensus
Bone
Research
Standardization
Health
Osteosclerosis
Monitoring
Extramedullary Hematopoiesis
Therapeutics
Myeloproliferative Disorders
Cachexia
Frustration
Pharmaceutical Preparations
Erythropoiesis
Hematopoietic Stem Cell Transplantation
Splenomegaly
Anemia
Stem Cells

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). / Tefferi, Ayalew; Barosi, Giovanni; Mesa, Ruben A.; Cervantes, Francisco; Deeg, H. Joachim; Reilly, John T.; Verstovsek, Srdan; Dupriez, Brigitte; Silver, Richard T.; Odenike, Olatoyosi; Cortes, Jorge; Wadleigh, Martha; Solberg, Lawrence A.; Camoriano, John K.; Gisslinger, Heinz; Noel, Pierre; Thiele, Juergen; Vardiman, James W.; Hoffman, Ronald; Cross, Nicholas C.P.; Gilliland, D. Gary; Kantarjian, Hagop.

In: Blood, Vol. 108, No. 5, 01.09.2006, p. 1497-1503.

Research output: Contribution to journalArticle

Tefferi, A, Barosi, G, Mesa, RA, Cervantes, F, Deeg, HJ, Reilly, JT, Verstovsek, S, Dupriez, B, Silver, RT, Odenike, O, Cortes, J, Wadleigh, M, Solberg, LA, Camoriano, JK, Gisslinger, H, Noel, P, Thiele, J, Vardiman, JW, Hoffman, R, Cross, NCP, Gilliland, DG & Kantarjian, H 2006, 'International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)', Blood, vol. 108, no. 5, pp. 1497-1503. https://doi.org/10.1182/blood-2006-03-009746
Tefferi, Ayalew ; Barosi, Giovanni ; Mesa, Ruben A. ; Cervantes, Francisco ; Deeg, H. Joachim ; Reilly, John T. ; Verstovsek, Srdan ; Dupriez, Brigitte ; Silver, Richard T. ; Odenike, Olatoyosi ; Cortes, Jorge ; Wadleigh, Martha ; Solberg, Lawrence A. ; Camoriano, John K. ; Gisslinger, Heinz ; Noel, Pierre ; Thiele, Juergen ; Vardiman, James W. ; Hoffman, Ronald ; Cross, Nicholas C.P. ; Gilliland, D. Gary ; Kantarjian, Hagop. / International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). In: Blood. 2006 ; Vol. 108, No. 5. pp. 1497-1503.
@article{d185d81000b14592878a56ab698846c8,
title = "International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis. Patients with MMM have shortened survival and their quality of life is compromised by progressive anemia, marked hepatosplenomegaly, and severe constitutional symptoms including cachexia. After decades of frustration with ineffective therapy, patients are now being served by promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and immunomodulatory drugs. Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2V617F), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response. Such progress calls for standardization of response criteria to accurately assess the value of new treatment modalities, to allow accurate comparison between studies, and to ensure that the definition of response reflects meaningful health outcome. Accordingly, an international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI). Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly.",
author = "Ayalew Tefferi and Giovanni Barosi and Mesa, {Ruben A.} and Francisco Cervantes and Deeg, {H. Joachim} and Reilly, {John T.} and Srdan Verstovsek and Brigitte Dupriez and Silver, {Richard T.} and Olatoyosi Odenike and Jorge Cortes and Martha Wadleigh and Solberg, {Lawrence A.} and Camoriano, {John K.} and Heinz Gisslinger and Pierre Noel and Juergen Thiele and Vardiman, {James W.} and Ronald Hoffman and Cross, {Nicholas C.P.} and Gilliland, {D. Gary} and Hagop Kantarjian",
year = "2006",
month = "9",
day = "1",
doi = "10.1182/blood-2006-03-009746",
language = "English (US)",
volume = "108",
pages = "1497--1503",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)

AU - Tefferi, Ayalew

AU - Barosi, Giovanni

AU - Mesa, Ruben A.

AU - Cervantes, Francisco

AU - Deeg, H. Joachim

AU - Reilly, John T.

AU - Verstovsek, Srdan

AU - Dupriez, Brigitte

AU - Silver, Richard T.

AU - Odenike, Olatoyosi

AU - Cortes, Jorge

AU - Wadleigh, Martha

AU - Solberg, Lawrence A.

AU - Camoriano, John K.

AU - Gisslinger, Heinz

AU - Noel, Pierre

AU - Thiele, Juergen

AU - Vardiman, James W.

AU - Hoffman, Ronald

AU - Cross, Nicholas C.P.

AU - Gilliland, D. Gary

AU - Kantarjian, Hagop

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis. Patients with MMM have shortened survival and their quality of life is compromised by progressive anemia, marked hepatosplenomegaly, and severe constitutional symptoms including cachexia. After decades of frustration with ineffective therapy, patients are now being served by promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and immunomodulatory drugs. Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2V617F), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response. Such progress calls for standardization of response criteria to accurately assess the value of new treatment modalities, to allow accurate comparison between studies, and to ensure that the definition of response reflects meaningful health outcome. Accordingly, an international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI). Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly.

AB - Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis. Patients with MMM have shortened survival and their quality of life is compromised by progressive anemia, marked hepatosplenomegaly, and severe constitutional symptoms including cachexia. After decades of frustration with ineffective therapy, patients are now being served by promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and immunomodulatory drugs. Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2V617F), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response. Such progress calls for standardization of response criteria to accurately assess the value of new treatment modalities, to allow accurate comparison between studies, and to ensure that the definition of response reflects meaningful health outcome. Accordingly, an international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI). Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly.

UR - http://www.scopus.com/inward/record.url?scp=33748205495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748205495&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-03-009746

DO - 10.1182/blood-2006-03-009746

M3 - Article

C2 - 16675707

AN - SCOPUS:33748205495

VL - 108

SP - 1497

EP - 1503

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -